{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:44:15Z","timestamp":1782978255645,"version":"3.54.5"},"reference-count":17,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Int"],"DOI":"10.3892\/mi.2026.327","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:12:40Z","timestamp":1781169160000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Post\u2011operative liver metastasis from gastric cancer with HER2\u2011positive areas newly identified upon re\u2011evaluation, leading to a favorable response to trastuzumab\u2011based therapy: A case report"],"prefix":"10.3892","volume":"6","author":[{"given":"Shinsuke","family":"Usui","sequence":"first","affiliation":[{"name":"Department of Surgery, Kashiwa Kousei General Hospital, Kashiwa, Chiba 277\u20118551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kashiwa Kousei General Hospital, Kashiwa, Chiba 277\u20118551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Sakon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kashiwa Kousei General Hospital, Kashiwa, Chiba 277\u20118551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kashiwa Kousei General Hospital, Kashiwa, Chiba 277\u20118551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Suwa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kashiwa Kousei General Hospital, Kashiwa, Chiba 277\u20118551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"key20260702095043_b1-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"key20260702095043_b2-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20260702095043_b3-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"key20260702095043_b4-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"key20260702095043_b5-MI-6-4-00327","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with microsatellite instability-high (MSI-H) advanced solid tumors: Results from the KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20260702095043_b6-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01): A randomised, open-label, phase 2 trial","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260702095043_b7-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 for first-line treatment of CLDN18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"key20260702095043_b8-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in patients with CLDN18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma (GLOW): A randomised, double-blind, phase 3 trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"key20260702095043_b9-MI-6-4-00327"},{"key":"key20260702095043_b10-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"key20260702095043_b11-MI-6-4-00327"},{"key":"key20260702095043_b12-MI-6-4-00327"},{"key":"key20260702095043_b13-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s10120-024-01571-w","article-title":"Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan","volume":"28","author":"Abe","year":"2025","journal-title":"Gastric Cancer"},{"key":"key20260702095043_b14-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2015.09.018","article-title":"Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)","volume":"53","author":"Park","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20260702095043_b15-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/ags3.12515","article-title":"International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1)","volume":"25","author":"Yoshida","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"key20260702095043_b16-MI-6-4-00327","first-page":"3775","article-title":"Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer: 3-year overall and recurrence-free survival","volume":"27","author":"Fujitani","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"key20260702095043_b17-MI-6-4-00327","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: The GO2 phase 3 randomized clinical trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Medicine International"],"original-title":[],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:50:48Z","timestamp":1782975048000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mi.2026.327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.3892\/mi.2026.327","relation":{},"ISSN":["2754-3242","2754-1304"],"issn-type":[{"value":"2754-3242","type":"print"},{"value":"2754-1304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}